Abstract
19P Mortality among EGFR-mutated advanced NSCLC patients after frontline osimertinib treatment: A real-world, US attrition analysis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1016/s1556-0864(23)00273-3
Journal: Journal of Thoracic Oncology | Publication Date: Apr 1, 2023 |
Citations: 1 | License type: publisher-specific-oa |
19P Mortality among EGFR-mutated advanced NSCLC patients after frontline osimertinib treatment: A real-world, US attrition analysis
Join us for a 30 min session where you can share your feedback and ask us any queries you have